Liquidia Technologies

Real-time Quotes | Nasdaq Last Sale

After Hours: 4.620 +0.075 +1.65% 18:09 10/23 EDT
Corp Actions
Cleveland BioLabs, Anchiano Therapeutics leads healthcare gainers, Baudax Bio, BOQI International Medical among major losers
Gainers: Cleveland BioLabs (CBLI) +96%, Anchiano Therapeutics (ANCN) +46%, Aptinyx (APTX) +45%, SOS (SOS) +21%, Liquidia Technologies (LQDA) +18%.Losers: Baudax Bio (BXRX) -37%, BOQI International Medical (BIMI) -13%, Midatech Pharma (MTP) -11%, China Jo-Jo Drugstores (CJJD) -9%, Calithera Biosciences (CALA) -9%.
Seekingalpha · 3d ago
Why Liquidia's Stock Is Trading Higher Today
Liquidia (NASDAQ: LQDA) shares are trading higher on Monday. The company said that on Oct. 16 it had received an unsolicited offer to enter into a License Agreement for the LIQ861 and has postponed its special meeting in order to fully consider the offer.
Benzinga · 4d ago
RESI, BSTC, WWR and NNDM among midday movers
Gainers: Kaixin Auto (KXIN) +317%.Dragon Victory International (LYL) +107%.Marine Petroleum Trust (MARPS) +62%.BOQI International Medical (BIMI) +59%.Dogness (DOGZ) +45%.Dunxin Financial (DXF) +44%.BioSpecifics Technologies (BSTC) +44%.Front Yard Residential (RESI) +35%.Liquidia Technologies (LQDA) +30%.Blonder Tongue Laboratories
Seekingalpha · 4d ago
BOQI International Medical, BioSpecifics Technologies leads healthcare gainers; Aerie Pharmaceuticals, ReWalk Robotics among major losers
Gainers: BOQI International Medical (BIMI) +70%, BioSpecifics Technologies (BSTC) +44%, Liquidia Technologies (LQDA) +19%, OraSure Technologies (OSUR) +17%, Centogene (CNTG) +17%.Losers: Aerie Pharmaceuticals (AERI) -14%, ReWalk Robotics (RWLK) -13%, Organogenesis Holdings (ORGO) -9%, ASLAN Pharmaceuticals (ASLN) -8%, Greenwich LifeSciences (GLSI) -7%.
Seekingalpha · 4d ago
Liquidia Announces Postponement Of Special Meeting Of Stockholders, Originally Scheduled Oct. 21
Liquidia Announces Postponement of Special Meeting of Stockholders RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ:LQDA), a late-stage clinical biopharmaceutical
Benzinga · 4d ago
Organogenesis Holdings, Anavex Life Sciences leads healthcare gainers; Vertex Pharmaceuticals, Aphria among major losers
Gainers: Organogenesis Holdings (ORGO) +22%, Anavex Life Sciences (AVXL) +16%, Precigen (PGEN) +12%, Replimune Group (REPL) +11%, Armata Pharmaceuticals (ARMP) +11%.Losers: Vertex Pharmaceuticals (VRTX) -20%, Aphria (APHA) -16%, Cyclerion Therapeutics (CYCN) -13%, Liquidia Technologies (LQDA) -9%, Arvinas (ARVN) -7%.
Seekingalpha · 10/15 15:12
Liquidia Provides Update on U.S. Patent Trial and Appeal Board Decision on Inter Partes Review of Two United Therapeutics Tyvaso® Patents
PTAB Institutes Inter Partes Review Proceeding Against United Therapeutics’ ‘901 Patent and Denies Institution on ‘066 Patent for Tyvaso®RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) against U.S. Patent No. 9,604,901 (‘901) and concurrently denied institution on 9,593,066 (‘066), both owned by United Therapeutics Corporation (UTC) and listed in the Orange Book for Tyvaso® (treprostinil). For ‘901, the PTAB Institution Decision states that “based on the information presented, we institute an inter partes review of claims 1–9 of the ’901 patent.”Conversely, for ‘066, the PTAB denied institution of IPR stating that the petition “has not established a reasonable likelihood that it would prevail in showing that at least one of the challenged claims is unpatentable.”“The PTAB’s decision to institute an IPR proceeding against the ‘901 patent for Tyvaso is another important step forward for Liquidia’s ongoing effort to bring LIQ861, a convenient and well tolerated treatment option, to the PAH community,” stated Neal Fowler, Chief Executive Officer at Liquidia. “We believe PTAB’s decision on ‘066 to be in error and while there are options for reconsideration, we remain confident in the arguments of non-infringement and invalidity to be made in district court.”Mr. Fowler added, “The Liquidia management team and our board are committed to providing PAH patients with alternative treatment options, like LIQ861, that we believe they need and deserve. We will not be deterred by any effort to limit our ability to deliver on this goal for patients and are confident in our options to bring LIQ861 to commercialization.”Liquidia’s 505(b)(2) New Drug Application (NDA) for LIQ861, a dry powder inhalation of treprostinil, is currently under active review by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH). Tyvaso®, a nebulized treprostinil solution, is the Reference Listed Drug for the LIQ861 NDA.On June 4th, UTC filed a lawsuit against Liquidia under the Hatch-Waxman Act, based on the LIQ861 NDA, for infringement of Tyvaso patents that triggered a 30-month stay on an FDA regulatory approval. The 30-month stay expires on the earlier of October 24, 2022 or resolution of the litigation, whichever occurs first.In July, UTC filed an amended complaint asserting infringement of an additional recently issued U.S. Patent No. 10,716,793 (‘793). Although UTC’s amended complaint brings the ‘793 patent into the pending lawsuit, the statutory 30-month stay on regulatory approval, is not associated with the allegations of infringement of the ‘793 patent and the allegations of infringement of this patent should have no effect on the FDA’s review of the LIQ861 NDA.About Liquidia Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit Statements Regarding Forward-Looking StatementsThis press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related timelines, including potential U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for LIQ861, the timeline or outcome related to our patent litigation pending in the U.S. District Court for the District of Delaware or two petitions for inter partes review with the Patent Trial and Appeal Board, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our and Liquidia Corporation’s filings with the Securities and Exchange Commission, including the risk that our proposed acquisition of RareGen, LLC is not consummated or that the expected benefits and synergies from the proposed acquisition are not realized, the impact of the coronavirus (COVID-19) outbreak on our company and our financial condition and results of operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.Contact Information Media: Michael Parks Corporate Communications 484.356.7105 michael.parks@liquidia.comInvestors: Jason Adair Vice President, Corporate Development and Strategy 919.328.4400
GlobeNewswire · 10/14 14:25
Liquidia Technologies Announces That U.S. Patent Trial And Appeal Board Has Ruled Against United Therapeutics On Tyvaso Patents
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel
Benzinga · 10/14 13:27
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LQDA. Analyze the recent business situations of Liquidia Technologies through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LQDA stock price target is 11.00 with a high estimate of 20.00 and a low estimate of 6.00.
Institutional Holdings
Institutions: 92
Institutional Holdings: 24.55M
% Owned: 65.03%
Shares Outstanding: 37.75M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Pharmaceuticals & Medical Research
Key Executives
Chairman/Independent Director
Stephen Bloch
Chief Executive Officer/Director
Neal Fowler
Chief Financial Officer
Steven Bariahtaris
Chief Operating Officer
Robert Lippe
Senior Vice President
Benjamin Maynor
Senior Vice President
Robert Roscigno
Senior Vice President
Jeri Thomas
Tushar Shah
Independent Director
Joanna Horobin
Independent Director
Arthur Kirsch
Independent Director
Katherine Rielly-Gauvin
Independent Director
Seth Rudnick
Independent Director
Raman Singh
Independent Director
Ralph Snyderman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LQDA
Liquidia Technologies, Inc. is a clinical biopharmaceutical company, which is focused on the developing and commercialization of human therapeutics using its PRINT technology. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The Company is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
Hot Stocks

Webull offers kinds of Liquidia Technologies Inc stock information, including NASDAQ:LQDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LQDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LQDA stock methods without spending real money on the virtual paper trading platform.